Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & ISI's SCI  
Users online: 2765  
Home | Subscribe | Feedback | Login 
About Latest Articles Back-Issues Articlesmenu-bullet Search Instructions Online Submission Subscribe Etcetera Contact
 
  NAVIGATE Here 
  Search
 
  
 RESOURCE Links
 ::  Similar in PUBMED
 ::  Search Pubmed for
 ::  Search in Google Scholar for
 ::  Article in PDF (775 KB)
 ::  Citation Manager
 ::  Access Statistics
 ::  Reader Comments
 ::  Email Alert *
 ::  Add to My List *
* Registration required (free) 

  IN THIS Article
 :: Acute Kidney Injury
 ::  Chronic Kidney D...
 ::  End-Stage Renal ...
 :: Kidney Transplant
 ::  Nephrology Respo...
 :: Renalism
 :: Diagnosis
 :: Therapy
 :: Vaccination
 :: Conclusions
 ::  References
 ::  Article Figures

 Article Access Statistics
    Viewed917    
    Printed18    
    Emailed0    
    PDF Downloaded7    
    Comments [Add]    

Recommend this journal


 


 
  Table of Contents     
EDITORIAL
Year : 2022  |  Volume : 68  |  Issue : 4  |  Page : 187-193

COVID-19: A nephrologists' perspective


Department of Nephrology, Seth GSMC and KEMH, Mumbai, Maharashtra, India

Date of Submission07-Jun-2022
Date of Decision02-Aug-2022
Date of Acceptance12-Sep-2022
Date of Web Publication04-Nov-2022

Correspondence Address:
T E Jamale
Department of Nephrology, Seth GSMC and KEMH, Mumbai, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jpgm.jpgm_470_22

Rights and Permissions




How to cite this article:
Jamale T E, Thakare S B. COVID-19: A nephrologists' perspective. J Postgrad Med 2022;68:187-93

How to cite this URL:
Jamale T E, Thakare S B. COVID-19: A nephrologists' perspective. J Postgrad Med [serial online] 2022 [cited 2022 Dec 1];68:187-93. Available from: https://www.jpgmonline.com/text.asp?2022/68/4/187/360455




After its identification in late 2019 in Wuhan, China as the cause of severe pneumonia, SARS-CoV-2 (COVID-19) pandemic spread to most parts of the world. SARS-CoV-2 virus primarily affects the respiratory system, with manifestations ranging from mild upper respiratory tract infection to severe acute respiratory distress syndrome, multiorgan dysfunction, and death. COVID-19 disproportionately affects patients with pre-existing comorbid conditions like diabetes, hypertension, and those with various types of kidney diseases. Severe COVID-19 is associated with a high risk of acute kidney injury (AKI). Patients with pre-existing kidney diseases, chronic kidney disease (CKD), end-stage renal disease (ESRD), and renal allograft recipients are amongst the most vulnerable subsets of patients. They have a high risk of getting infected, are more likely to develop severe disease, and also experience high mortality.


 :: Acute Kidney Injury Top


Although reported incidence of AKI in COVID-19 varies widely depending upon the population characteristics under study, it is consistently reported to be much higher (30%-50%) than adults hospitalized for reasons not related to COVID-19.[1] AKI developing in these patients portends a poor prognosis, with reported mortality rates as high as 60%.[2] The excess risk of AKI is only partially explained by the traditional risk factors like advanced age, hypertension, diabetes, and baseline CKD.[3]

AKI in COVID-19 is multifactorial. Apart from traditional risk factors like hypovolemia, hemodynamic instability, exposure to nephrotoxic drugs (like nonsteroidal anti-inflammatory agents, antibiotics), and superimposed sepsis contributing to the development of AKI, other factors specific to the pathophysiology of COVID-19 like inflammation, immune activation, tissue hypoxia, increased intrarenal pressure, microthrombosis, and direct viral cytopathic effects also play a role.[4] COVID-19 is characterized by severe systemic inflammation and a procoagulant state, both of which may induce AKI by tubular injury and renal microthrombi, leading to further ischemic tubular damage. Immunological injury, to the glomerulus and tubulointerstitial compartment, is also hypothesized to be a contributor to the damage.[4] Angiotensin-converting enzyme 2 (ACE2) receptors are richly expressed in the kidney parenchyma, which may explain the susceptibility to kidney injury in COVID-19.[5] Several initial reports demonstrated presence of virus in the tubular epithelial cells,[6] however, these have not been substantiated by others.[7] The role of direct viral cytopathic effect remains uncertain. This is especially because endosomal subcellular structures like clathrin-coated vesicles and multivesicular bodies can mimic viral particles on ultrastructural examination. While all of the aforesaid factors are proposed as mechanisms of AKI, the exact role and relative contribution of each of them is debated, and a unifying mechanism of AKI in COVID-19 remains to be defined. Rather than being mutually exclusive, different factors may play a dominant role in different patients and also the predominant factor may vary in an individual patient at different points of time during the course of the disease [Figure 1].
Figure 1: Major contributors to COVID-19–related AKI. AKI in COVID-19 is multifactorial and one or more factors may be predominant at different time points in course of the disease. Renal injury may be maintained by persistence of insults such as inflammation, ischemia, and maladaptive repair pathways

Click here to view


Most patients with AKI present with asymptomatic rise in the blood urea nitrogen and creatinine, and close monitoring for the development of complications of AKI is needed. Of note, proteinuria and hematuria are observed in about 80% of the cases,[8] unlike other settings of AKI where it would raise the suspicion of acute nephritis. Some experts have suggested the use of early renal support with continuous renal replacement therapy (CRRT).[9] However, there are no data supporting preferential use of CRRT. Cytokine levels in COVID-19 are reported to be much lower than sepsis,[10] a condition where strategies of early and aggressive renal support with the hope of cytokine removal were not found to be useful. Instead, close monitoring of the patient's volume status, acid base and electrolyte homeostasis, and initiation of renal support whenever indicated seems to be a prudent approach.[11] Intermittent hemodialysis (IHD), sustained low efficiency dialysis (SLED), peritoneal dialysis (PD), and CRRT are all valid modalities of renal support in these patients based upon the available evidence in critically ill patients with AKI.[12] IHD and SLED can be easily set up at bed side and are particularly suited, given the logistic challenge of dialyzing large number of patients during a pandemic. PD is another modality that facilitates dialysis at home for mild cases, reduces exposure to healthcare, and is efficacious. PD effluent has not been found to contain significant viral load and thus PD is not considered to involve a significant risk for the spread of infection.[13]

One of the important characteristics of COVID-19 AKI is its dismal prognosis which is far worse both in terms of patient[2] and renal survival.[8] Our patient cohort had high rates of dialysis requiring AKI (2.73%), high mortality (43.9%), and an alarmingly high rate (67.7%) of dialysis dependency at discharge.[14] High mortality rates are consistently reported, although these might be decreasing,[15] a significant number of AKI survivors remains dialysis dependent,[8] thus further contribute to the excess burden of CKD and ESRD in population.


 :: Chronic Kidney Disease Top


CKD not only increases the susceptibility to develop infection but also increases the risk of developing severe disease, superimposed AKI, and further on, the risk of permanent loss of kidney function.[16],[17] Prevalence of CKD was significantly higher in patients with severe COVID-19 in a meta-analysis of 4 studies involving 1,389 patients.[16] Our patient cohort had a high prevalence of hypertension (77.3%) and CKD (77.6%) at baseline.

Use of ACE inhibitors increases the level of ACE2 and it was initially speculated that this increases the risk of severe disease.[18] However, a randomized controlled trial and several observational studies failed to show any such association.[19],[20] Withholding these drugs may lead to exacerbation of hypertension and heart failure, which may in turn lead to increased mortality and hence is not recommended. However, in patients with COVID-19, absolute or relative hypotension is common and antihypertensive medications may be required to be withheld or decreased. This practice is supported by a large randomized controlled trial[21] which observed the reduced risk of AKI with a higher mean arterial pressure target in patients with baseline hypertension.


 :: End-Stage Renal Disease Top


Patients on dialysis for ESRD are particularly susceptible to infection with COVID-19 due to multiple factors.[22] In addition to highly prevalent comorbidities like diabetes, hypertension, and cardiovascular disease increasing susceptibility, increased exposure during travel to the dialysis centre 3 times per week, and during the dialysis procedure, may be significant factors. Supporting this hypothesis, a study reported significantly lower incidence of COVID-19 in patients on home-based dialysis (PD or HD) than those on in-centre dialysis.[23] ESRD patients also develop severe disease and experience one of the highest reported mortality rates due to COVID-19.[24] A report from India[25] highlighted the significantly higher mortality (32.7%) in the second wave of the pandemic as compared to the first wave and pre-COVID-19 mortality rates. Patients with fever and upper respiratory tract symptoms should be dialyzed preferably in a 'suspect area' and if not possible, then in the last shift, and at the end of the row with adequate distancing and barrier precautions. Distancing and other respiratory precautions should be observed in the waiting area as well.[26]

Management of hospitalized patients with COVID-19 and ESRD is particularly challenging not only due to illness severity but also due to multiple comorbidities and need of interdisciplinary care. Renal replacement therapy needs to be continued during hospital stay with a modality that suits the hemodynamic needs of a given patient. Many symptoms overlap between severe COVID-19 and ESRD (dyspnea, fatigue, and chest X-ray findings of fluid overload) and this can delay the recognition of severe disease. Initial high mortality may be due to absence of early warning signs or quick deterioration in the later course of the disease, highlighting need for careful triage at initial evaluation.[27] Non-COVID-19 factors like dialysis access dysfunction or failure, access-related sepsis, missed dialysis sessions, inadequate dialysis, inadequate supply of dialysis consumables due to lockdown also played a crucial role in the reported high mortality in the first two waves. Thus, the susceptibility to COVID-19 and poor outcomes in ESRD is a composite effect of multiple factors[28],[29] [Figure 2] and multifaceted interventions are hence needed to manage these patients. We and others have reported successful use of citywide dashboard for timely allocation of the dialysis slots and hospital beds.[30] Quick expansion of the facilities to cater to the increasing number of admitted ESRD patients, colocalizing infected dialysis patients to a single ward or floor, bedside dialysis facility, and dedicated COVID-19 dialysis staff is needed to optimally care for these patients as discussed later in our experience of High Dependency Renal Unit (HDRU).
Figure 2: Major contributors to mortality in ESRD due to COVID-19. In addition to the higher prevalence of traditional risk factors for death like age, hypertension, diabetes, cardiovascular disease; ESRD specific causes contribute to excess mortality in COVID-19. (CRBSI- Catheter related blood-stream infection)

Click here to view


Most dialysis patients are on erythropoiesis stimulating agents, and due to the risk of thrombosis with these, some experts have suggested lowering the target hemoglobin level.[31] However, in our opinion, this decision should be individualized based on the severity of COVID-19, symptoms of anemia, and candidacy for kidney transplant after duly considering the risk of HLA (Human Leukocyte Antigen) sensitization after blood transfusion.


 :: Kidney Transplant Top


It is reasonable to defer elective live donor kidney transplant surgeries during the peak of a pandemic wave; however, life-saving deceased donor transplant offers need not be refused.[32] Donor and recipient both should be tested by Nucleic Acid Amplification Test (NAAT) within 48-72 hours of the surgery. There have been reports of successful use of nonrespiratory organs from donors dying from COVID-19. Frequency and magnitude of viremia is low and blood-borne spread is not considered important.[33]

Clinical features of COVID-19 in kidney transplant recipients may be atypical; patients can present with diarrhea, respiratory distress without preceding upper respiratory tract symptoms, and even without fever. We reported a high incidence of diarrhea (52%) and anemia (82%) as a presenting feature.[34] In our cohort, kidney transplant recipients with a low baseline cardiovascular risk were also observed to develop myocardial injury and arrhythmias, solely because of severe COVID-19 disease.[35] Our treatment strategies included antimetabolite withdrawal (85%), calcineurin inhibitor (CNI) decrease or withdrawal (64%), increased steroids (53%), hydroxychloroquine (21%), remdesivir (28.3%), and tocilizumab (3.3%). Persistent swab positivity at discharge was also observed in our patients. Initial reports showed high mortality in transplant recipients,[36],[37] while a subsequent large multicenter study done later showed a much lower risk of death.[38] Significant interaction of the baseline comorbidities like diabetes and hypertension make it difficult to assess the impact of kidney transplant on risk of infection, illness severity, and death.

In hospitalized patients with moderate or severe disease, it is suggested to reduce or stop the antimetabolite (azathioprine or mycophenolate). In those with progressive disease, further reduction in immunosuppression may be needed and this decision should be individualized based on the risk and history of rejection vis-a-vis the risk of severe disease. CNIs (tacrolimus and cyclosporine) inhibit IL6 and IL1 pathways which are important in pathogenesis of severe COVID-19 and therefore may the be continued as far as possible.[39]

In our experience,[40] risk of AKI in kidney transplant recipients was much higher than the reported literature[39] and may be related to multiple factors. Late presentation with severe disease, relative hypotension, and a lack of autoregulation in the kidney allograft increase risk of AKI. Moreover, tacrolimus toxicity contributing to AKI was noted in a large number of kidney allograft recipients hospitalized for COVID-19.[41] Tacrolimus level may be increased due to diarrhea (a common presenting feature), which is known to increase tacrolimus exposure. Whether COVID-19 alters P450 expression leading to higher tacrolimus levels remains to be seen. In one of the few studies of long duration follow-up after COVID-19, AKI in a cohort of veterans was observed to be protracted, with a large number of patients having residual renal damage[42] at 12 months after COVID-19. This has major implications for those with kidney transplant, given the fact that chronic allograft injury is cited as the most common cause of graft loss in long term.


 :: Nephrology Response to COVID-19 Top


The city of Mumbai saw its first case of COVID-19 on March 11, 2020. Institutional dialysis services all over the country faced challenges like outbreaks among patients and staff, frequent closures, lack of guiding policies, and expensive and often unavailable infection control measures.[43] In addition, disruption of hospital services, transport barriers, shortage of drugs, and consumables directly impacted morbidity index, rates of hospitalization, and death.[44] Existing public sector infrastructure for dialysis was put to immense strain. An urgent need to create more facilities to accommodate this large number of patients with ESRD and COVID-19 emerged. India has an estimated 1,75,000 patients of ESRD on chronic dialysis across the country.[45] The city of Mumbai alone has 174 dialysis centers with 10,000 dialysis patients on regular dialysis within the city. Dedicated COVID-19 hospitals were specially created by the Brihanmumbai Municipal Corporation during the pandemic. Few such designated units were also capable of providing bedside dialysis and managing critically ill patients with severe COVID-19 and ESRD. Another novel initiative which addressed this crisis in Mumbai was the multicenter 'Project Victory', where a citywide dashboard was created to facilitate timely allocation of dialysis slots to patients on maintenance dialysis as soon as they were detected COVID-19 positive.[30] More than 1,000 patients could be allocated a slot at a COVID-19 dialysis facility within 48 hours through this portal. This served the purpose of optimum utilization of existing dialysis resources.

High mortality continued to be a cause of concern for patients with renal failure and COVID-19, with almost one-third of the patients on dialysis experiencing mortality. At our centre, we audited the outcomes of hospitalized patients with COVID-19 who also had severe renal failure needing dialysis. Several gaps and logistic challenges in the process of the care were identified and to address them a high dependency renal unit (HDRU) was commissioned [Figure 3]. Concept of HDRU[14] was based upon the unique medical needs of these patients: regular and adequate dialysis, quick identification and addressal of dialysis access dysfunction, prompt management of blood stream infections, triage of the patients for close monitoring and intensive care unit transfers, and interdisciplinary care involving intensivists, cardiologists, pulmonologists, and endocrinologists. HDRU was managed by nephrologists acting as primary care physicians. Key components of HDRU included checklist-based close clinical monitoring, care bundle approach focusing on key clinical issues, integration of multispecialty care by the primary care physician-nephrologists, and training of personnel with respect to management of COVID-19 and kidney specific issues.
Figure 3: Structure of HDRU and components of care delivery in HDRU, *POCUS- Point of care ultrasound

Click here to view


Of 4,254 COVID-19 positive patients admitted to our hospital from March 28, 2020 to September 30, 2020, 238 (5.59%) patients had severe renal impairment (AKI requiring dialysis: 116, ESRD: 122). From May 29 to August 31, 160 of these patients received treatment in HDRU. A significant decline in the mortality of patients was observed after implementation of HDRU as a quality improvement initiative. Seventy six (31.9%) of 238 patients died [AKI-D: 51 (43.9%), ESRD: 25 (21.2%)]. Nineteen (36.5%) and 35 (21.9%) patients died in the pre-HDRU and post-HDRU groups. 41 kidney transplant recipients were also treated in the HDRU and this cohort reported one of the lowest mortality rates of COVID-19 in solid organ transplant recipients.[46] Although limited by an observational design, our results suggest that HDRU is a feasible and potentially effective approach in management of COVID-19 in patients with severe renal function impairment.


 :: Renalism Top


The term renalism is used to describe therapeutic nihilism for renal patients leading to the inappropriately low rates of diagnostic and therapeutic interventions in patients with kidney disease.[47] This is largely due to the lack of inclusion of patients with decreased kidney function in pivotal drug trials and concern of nephrotoxicity leading to weak recommendations or none at all for the use of therapeutic drugs in these patients.


 :: Diagnosis Top


Contrast enhanced computed tomography (CT) scan or CT pulmonary imaging which is crucial in the diagnosis, risk assessment, and therapy is often deferred in such patients due to the concerns of contrast induced AKI; however, the risk of this complication is significantly lower than believed,[48] and if indicated, these imaging modalities should not be withheld for decreased kidney function.


 :: Therapy Top


Due to immunosuppression and decreased kidney function, many of these patients qualify for antibody cocktails and antivirals (e.g., nirmatrelvir-ritonavir) to prevent severe disease. However, the later should be used with extreme caution[49] and close monitoring, due to a major interaction of this antiviral with CNIs- tacrolimus and cyclosporine. Careful consideration of risk benefit is necessary before starting this therapy and therapeutic drug monitoring with dose reduction is needed to avoid acute CNI toxicity.

Remdesivir and dexamethasone can be safely used whenever indicated with monitoring for severe disease. Remdesivir was approved by the United States Food and Drug Administration in October 2020, based on the results of RECOVERY trial,[50] showing decreased time to recovery in the treated patients; however, drug was largely avoided in patients with kidney diseases for the lack of data and theoretical risk of nephrotoxicity due to its vehicle cyclodextrin. We first reported the use of remdesivir in 46 patients with a wide range of renal function abnormalities including AKI, CKD, ESRD, and kidney transplant recipients and found it to be largely safe with no signal of nephrotoxicity attributable to remdesivir.[51] These findings were later substantiated by a number of reports from other countries.[52],[53]


 :: Vaccination Top


Vaccine response to mRNA vaccines is poor in organ transplant recipients.[54] However, one published[55] and our unpublished data from India have shown excellent seroconversion rates (>80%) even with single dose of Oxford-Astra Zeneca vaccine. This may be related to the younger age, lower comorbidity burden, and possibly high rates of symptomatic and subclinical infection. Vaccination effectively prevents severe disease and death even after one dose of the vaccine,[56] thus wider vaccine coverage in patients with kidney disease is needed.


 :: Conclusions Top


COVID-19 is thus a cause of significant morbidity and mortality in patients with various kidney diseases. Multiple factors related and unrelated to COVID-19 contribute to adverse outcomes. Approaches to improve outcomes in this vulnerable population are urgently needed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
 :: References Top

1.
Robbins-Juarez SY, Qian L, King KL, Stevens JS, Husain SA, Radhakrishnan J, et al. Outcomes for patients with COVID-19 and acute kidney injury: A systematic review and meta-analysis. Kidney Int Rep 2020;5:1149-60.  Back to cited text no. 1
    
2.
Gupta S, Coca SG, Chan L, Melamed ML, Brenner SK, Hayek SS, et al. AKI treated with renal replacement therapy in critically ill patients with covid-19. J Am Soc Nephrol 2021;32:161-76.  Back to cited text no. 2
    
3.
Moledina DG, Simonov M, Yamamoto Y, Alausa J, Arora T, Biswas A, et al. The association of covid-19 with acute kidney injury independent of severity of illness: A multicenter cohort study. Am J Kidney Dis 2021;77:490-9.e1.  Back to cited text no. 3
    
4.
Legrand M, Bell S, Forni L, Joannidis M, Koyner JL, Liu K, et al. Pathophysiology of COVID-19-associated acute kidney injury. Nat Rev Nephrol 2021;17:751-64.  Back to cited text no. 4
    
5.
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271-80.e8.  Back to cited text no. 5
    
6.
Braun F, Lütgehetmann M, Pfefferle S, Wong MN, Carsten A, Lindenmeyer MT, et al. SARS-CoV-2 renal tropism associates with acute kidney injury. Lancet 2020;396:597-8.  Back to cited text no. 6
    
7.
May RM, Cassol C, Hannoudi A, Larsen CP, Lerma EV, Haun RS, et al. A multi-center retrospective cohort study defines the spectrum of kidney pathology in Coronavirus 2019 Disease (COVID-19). Kidney Int 2021;100:1303-15.  Back to cited text no. 7
    
8.
Chan L, Chaudhary K, Saha A, Chauhan K, Vaid A, Zhao S, et al. Mount Sinai COVID Informatics Center (MSCIC). AKI in hospitalized patients with COVID-19. J Am Soc Nephrol 2021;32:151-60.  Back to cited text no. 8
    
9.
Ronco C, Reis T, Husain-Syed F. Management of acute kidney injury in patients with COVID-19. Lancet Respir Med 2020;8:738-42.  Back to cited text no. 9
    
10.
Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, et al. Cytokine elevation in severe and critical COVID-19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med 2020;8:1233-44.  Back to cited text no. 10
    
11.
Gaudry S, Hajage D, Benichou N, Chaïbi K, Barbar S, Zarbock A, et al. Delayed versus early initiation of renal replacement therapy for severe acute kidney injury: A systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet 2020;395:1506-15.  Back to cited text no. 11
    
12.
Zhou X, Dong P, Pan J, Wang H, Xu Z, Chen B. Renal replacement therapy modality in critically ill patients with acute kidney injury-A network meta-analysis of randomized controlled trials. J Crit Care 2021;64:82-90.  Back to cited text no. 12
    
13.
El Shamy O, Vassalotti JA, Sharma S, Aydillo-Gomez T, Marjanovic N, Ramos I, et al. Coronavirus disease 2019 (COVID-19) hospitalized patients with acute kidney injury treated with acute peritoneal dialysis do not have infectious peritoneal dialysis effluent. Kidney Int 2020;98:782.  Back to cited text no. 13
    
14.
Thakare S, Modi T, Gandhi C, Bose S, Deb S, Katyal A, et al. High dependency renal unit for the management of COVID-19 in patients with severe acute or chronic kidney disease. Medicine (Baltimore) 2022;101:e30423.  Back to cited text no. 14
    
15.
Charytan DM, Parnia S, Khatri M, Petrilli CM, Jones S, Benstein J, et al. Decreasing incidence of acute kidney injury in patients with COVID-19 critical illness in New York City. Kidney Int Rep 2021;6:916-27.  Back to cited text no. 15
    
16.
Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol 2020;52:1193-4.  Back to cited text no. 16
    
17.
Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. China medical treatment expert group for covid-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis. Eur Respir J 2020;55:2000547.  Back to cited text no. 17
    
18.
Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020;8:e21.  Back to cited text no. 18
    
19.
Lopes RD, Macedo AVS, de Barros E Silva PGM, Moll-Bernardes RJ, Dos Santos TM, Mazza L, et al. Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: A randomized clinical trial. JAMA 2021;325:254-64.  Back to cited text no. 19
    
20.
Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin-angiotensin-aldosterone system inhibitors and risk of covid-19. N Engl J Med 2020;382:2441-8.  Back to cited text no. 20
    
21.
Asfar P, Meziani F, Hamel JF, Grelon F, Megarbane B, Anguel N, et al. High versus low-blood pressure target in patients with septic shock. N Engl J Med 2014;370:1583-93.  Back to cited text no. 21
    
22.
Kooman JP, van der Sande FM. COVID-19 in ESRD and acute kidney injury. Blood Purif 2021;50:610-20.  Back to cited text no. 22
    
23.
Perl J, Thomas D, Tang Y, Yeung A, Ip J, Oliver MJ, et al. COVID-19 among adults receiving home versus in-center dialysis. Clin J Am Soc Nephrol 2021;16:1410-2.  Back to cited text no. 23
    
24.
Flythe JE, Assimon MM, Tugman MJ, Chang EH, Gupta S, Shah J, et al. Characteristics and outcomes of individuals with pre-existing kidney disease and COVID-19 admitted to intensive care units in the United States. Am J Kidney Dis 2021;77:190-203.e1.  Back to cited text no. 24
    
25.
Kakkanattu TJ, Sankarasubbaiyan S, Yadav AK, Kundu M, Gowda Bg M, Kumar V, et al. Outcome and determinants of outcome of covid-19 infection among hemodialysis patients: Findings from a national dialysis network program in India. Kidney Int Rep 2021;6:1429-32.  Back to cited text no. 25
    
26.
Director General of Health Services, Ministry of Health and Family Welfare, Guidelines for Dialysis of COVID-19 patients. New Delhi: EMR Division. Available from: https://www.mohfw.gov.in/pdf/GuidelinesforDialysisofCovid19 Patients.pdf. [Last accessed on 2022 Jun 04].  Back to cited text no. 26
    
27.
Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, et al. A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection. Kidney Int 2020;98:20-6.  Back to cited text no. 27
    
28.
Dai L, Schurgers LJ, Shiels PG, Stenvinkel P. Early vascular ageing in chronic kidney disease: Impact of inflammation, vitamin K, senescence and genomic damage. Nephrol Dial Transplant 2020;35(Suppl 2):ii31-7.  Back to cited text no. 28
    
29.
Ducloux D, Legendre M, Bamoulid J, Saas P, Courivaud C, Crepin T. End-stage renal disease-related accelerated immune senescence: Is rejuvenation of the immune system a therapeutic goal? Front Med (Lausanne) 2021;8:720402.  Back to cited text no. 29
    
30.
Billa V, Noronha S, Bichu S, Kothari J, Kumar R, Mehta K, et al. A unified citywide dashboard for allocation and scheduling dialysis for COVID-19 patients on maintenance hemodialysis. Indian J Nephrol 2022;32:197-205.  Back to cited text no. 30
  [Full text]  
31.
Fishbane S, Hirsch JS. Erythropoiesis-stimulating agent treatment in patients with covid-19. Am J Kidney Dis 2020;76:303-5.  Back to cited text no. 31
    
32.
Indian Society of Organ Transplantation. ISOT Position Statement for Transplantation in Era of COVID-19; c2020-21. Available from: https://isot.co.in/file/ISOT_V2_28_April_2020.pdf. [Last accessed on 2022 Jun 04].  Back to cited text no. 32
    
33.
Chang L, Yan Y, Wang L. Coronavirus disease 2019: Coronaviruses and blood safety. Transfus Med Rev 2020;34:75-80.  Back to cited text no. 33
    
34.
Bajpai D, Deb S, Bose S, Gandhi C, Modi T, Katyal A, et al. Recovery of kidney function after AKI because of COVID-19 in kidney transplant recipients. Transpl Int 2021;34:1074-82.  Back to cited text no. 34
    
35.
Patil A, Rao N, Kumar K, Modi T, Gandhi C, Deb S, et al. Cardiovascular complications in kidney transplant recipients with COVID-19: A case series. Indian J Nephrol 2022;32:506-11.  Back to cited text no. 35
  [Full text]  
36.
Domínguez-Gil B, Fernández-Ruiz M, Hernández D, Crespo M, Colmenero J, Coll E, et al. Organ donation and transplantation during the covid-19 pandemic: A summary of the Spanish experience. Transplantation 2021;105:29-36.  Back to cited text no. 36
    
37.
Bossini N, Alberici F, Delbarba E, Valerio F, Manenti C, Possenti S, et al. Kidney transplant patients with SARS-CoV-2 infection: The Brescia renal COVID task force experience. Am J Transplant 2020;20:3019-29.  Back to cited text no. 37
    
38.
Kute VB, Bhalla AK, Guleria S, Ray DS, Bahadur MM, Shingare A, et al. Clinical profile and outcome of COVID-19 in 250 kidney transplant recipients: A multicenter cohort study from India. Transplantation 2021;105:851-60.  Back to cited text no. 38
    
39.
Willicombe M, Thomas D, McAdoo S. COVID-19 and calcineurin inhibitors: Should they get left out in the strom? J Am Soc Nephrol 2020;31:1145-6.  Back to cited text no. 39
    
40.
Oto OA, Ozturk S, Turgutalp K, Arici M, Alpay N, Merhametsiz O, et al. Predicting the outcome of COVID-19 infection in kidney transplant recipients. BMC Nephrol 2021;22:100.  Back to cited text no. 40
    
41.
Bajpai D, Saxena N, Gandhi C, Modi T, Bose S, Deb S, et al. Does COVID-19 increase tacrolimus levels in kidney transplant recipients? J Clin Pharm Ther 2022;47:707-8.  Back to cited text no. 41
    
42.
Bowe B, Xie Y, Xu E, Al-Aly Z. Kidney outcomes in long COVID. J Am Soc Nephrol 2021;32:2851-62.  Back to cited text no. 42
    
43.
Prasad N, Bhatt M, Agarwal SK, Kohli HS, Gopalakrishnan N, Fernando E, et al. The adverse effect of covid pandemic on the care of patients with kidney diseases in India. Kidney Int Rep 2020;5:1545-50.  Back to cited text no. 43
    
44.
Jain R, Dupas P. The effects of India's COVID-19 lockdown on critical non-COVID health care and outcomes: Evidence from dialysis patients. Soc Sci Med 2022;296:114762.  Back to cited text no. 44
    
45.
Bharati J, Jha V. Global dialysis perspective: India. Kidney360 2020;1:1143-7.  Back to cited text no. 45
    
46.
Bajpai D, Deb S, Bose S, Gandhi CP, Modi T, Katyal A, et al. Clinical course and outcomes of COVID-19 in kidney transplant recipients. Indian J Nephrol 2022;32:467-75.  Back to cited text no. 46
  [Full text]  
47.
Chertow GM, Normand SL, McNeil BJ. “Renalism”: Inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency. J Am Soc Nephrol 2004;15:2462-8.  Back to cited text no. 47
    
48.
Davenport MS, Perazella MA, Yee J, Dillman JR, Fine D, McDonald RJ, et al. Use of intravenous iodinated contrast media in patients with kidney disease: Consensus statements from the American College of Radiology and the National Kidney Foundation. Radiology 2020;294:660-8.  Back to cited text no. 48
    
49.
Food and Drug Administration. Silver Spring, MD: Important Dispensing Information; c2022-23 [Updated 2022 Apr 14]. Available from: https://www.fda.gov/media/155071/download. [Last accessed on 2022 Jun 04].  Back to cited text no. 49
    
50.
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 - Final report. N Engl J Med 2020;383:1813-26.  Back to cited text no. 50
    
51.
Thakare S, Gandhi C, Modi T, Bose S, Deb S, Saxena N, et al. Safety of remdesivir in patients with acute kidney injury or CKD. Kidney Int Rep 2021;6:206-10.  Back to cited text no. 51
    
52.
Ackley TW, McManus D, Topal JE, Cicali B, Shah S. A valid warning or clinical lore: An evaluation of safety outcomes of remdesivir in patients with impaired renal function from a multicenter matched cohort. Antimicrob Agents Chemother 2021;65:e02290-20.  Back to cited text no. 52
    
53.
Estiverne C, Strohbehn IA, Mithani Z, Hirsch JS, Wanchoo R, Goyal PG, et al. Remdesivir in patients with estimated GFR <30 ml/min per 1.73 m2 or on renal replacement therapy. Kidney Int Rep 2021;6:835-8.  Back to cited text no. 53
    
54.
Grupper A, Rabinowich L, Schwartz D, Schwartz IF, Ben-Yehoyada M, Shashar M, et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant 2021;21:2719-26.  Back to cited text no. 54
    
55.
Prasad N, Yadav B, Singh M, Gautam S, Bhadauria D, Patel M, et al. Humoral immune response of SARS-CoV-2 infection and anti-SARS-CoV-2 vaccination in renal transplant recipients. Vaccines (Basel) 2022;10:385.  Back to cited text no. 55
    
56.
Yadav AK, Sankarasubbaiyan S, Gowda Bg M, Shah K, Jha V. The high mortality and impact of vaccination on COVID-19 in hemodialysis population in India during the second wave. Kidney Int Rep 2021;6:2731.  Back to cited text no. 56
    


    Figures

  [Figure 1], [Figure 2], [Figure 3]



 

Top
Print this article  Email this article
 
Online since 12th February '04
2004 - Journal of Postgraduate Medicine
Official Publication of the Staff Society of the Seth GS Medical College and KEM Hospital, Mumbai, India
Published by Wolters Kluwer - Medknow